Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Breast 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 7Breast Neoplasms 6Colorectal Neoplasms 4Ovarian Neoplasms 3Neuroblastoma 3Neoplasm Metastasis 3Uveal Melanoma 2Unspecified Adult Solid Tumor, Protocol Specific 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Adenocarcinoma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

pembrolizumab 30Nivolumab 15Paclitaxel 13Cyclophosphamide 12Carboplatin 12sacituzumab govitecan 8Cisplatin 8Capecitabine 7130-nm albumin-bound paclitaxel 7Gemcitabine 6fludarabine 5durvalumab 5avelumab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Biopsy 5camrelizumab 4Specimen Handling 4Interleukin-2 4Injections 4Immune Checkpoint Inhibitors 4Docetaxel 4toripalimab 3talazoparib 3Leucovorin 3Everolimus 3Clinical Trials, Phase II as Topic 3Bevacizumab 3yeast-CEA vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Triple Negative Breast Neoplasms × sargramostim × Clear all
NCT05269381 2026-03-12

PNeoVCA

Mayo Clinic

Phase 1/2 Recruiting
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡